Elevated lipoprotein(a) levels (>30 mg/dL) were significantly more prevalent in patients with coronary artery disease compared to healthy controls, increasing the odds of CAD by 88% (OR 1.88).
Observational (n=3,710)
No
Lipoprotein(a) levels are significantly higher in Japanese patients with acute and chronic coronary syndromes compared to healthy controls, reinforcing its utility as an independent risk marker for coronary artery disease.
Effect estimate: OR 1.88 (95% CI 1.58-2.25)
Absolute Event Rate: 22.3% vs 13.1%
p-value: p=<0.001
Background: Lipoprotein(a) is a risk factor for atherosclerotic cardiovascular disease (ASCVD). However, its distribution based on coronary artery disease (CAD) in the Japanese population remains unclear. We compared lipoprotein(a) distributions among patients with acute coronary syndrome (ACS), patients with chronic coronary syndrome (CCS), and controls.
Okada et al. (Mon,) conducted a observational in Coronary Artery Disease (ACS and CCS) (n=3,710). Lipoprotein(a) assessment vs. Healthy controls was evaluated on Elevated Lipoprotein(a) >30 mg/dL (OR 1.88, 95% CI 1.58-2.25, p=<0.001). Elevated lipoprotein(a) levels (>30 mg/dL) were significantly more prevalent in patients with coronary artery disease compared to healthy controls, increasing the odds of CAD by 88% (OR 1.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: